New combo therapy shows promise for Hard-to-Treat CML
NCT ID NCT03578367
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study looked at adding a new drug, asciminib, to the standard treatment imatinib for people with chronic myeloid leukemia (CML) who hadn't reached very low levels of cancer cells. 104 adults who had been on imatinib for at least a year were randomly assigned to add asciminib, stay on imatinib alone, or switch to another drug called nilotinib. The goal was to see if the combination could help more patients achieve a deep molecular response, meaning very few cancer cells remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Georgia Regents University
Augusta, Georgia, 30912, United States
-
Novartis Investigative Site
Vienna, 1140, Austria
-
Novartis Investigative Site
Montreal, Quebec, H1T 2M4, Canada
-
Novartis Investigative Site
Brno, 625 00, Czechia
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Krakow, 31 531, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Wroclaw, 50 367, Poland
-
Novartis Investigative Site
Lisbon, 1099-023, Portugal
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Moscow, 125167, Russia
-
Novartis Investigative Site
Moscow, 125284, Russia
-
Novartis Investigative Site
Saint Petersburg, 191024, Russia
-
Novartis Investigative Site
Saint Petersburg, 197341, Russia
-
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, 11759, South Korea
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Changhua, 50006, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
-
Novartis Investigative Site
Liverpool, CH63 4JY, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.